Cancer immunotherapy, in contrast, can be affected not only by the molecular expression of the drug target (e.g., PD1/PD-L1 expression in immune checkpoint inhibition therapy) but also by the tumor mutational burden as well as the complex and dynamic immune components at play. This evidence concerns the gene CD274 and neoplasm.